NFLX vs PFE: Which Is the Better Buy?
Side-by-side comparison of Netflix, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Netflix, Inc. · Communication Services
$91.02
+95.7% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+35.4% upside to fair value
Grade B
QuantHub Verdict
NFLX has more upside to fair value
(+95.7%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NFLX |
PFE |
| Current Price |
$91.02 |
$26.33 |
| Fair Value Estimate |
$178.10 |
$35.65 |
| Upside to Fair Value |
+95.7%
|
+35.4%
|
| Market Cap |
$383.3B |
$149.8B |
| Forward P/E |
28.7x
|
19.3x
|
| EV / EBITDA |
11.4x
|
12.9x
|
| Price / Sales |
8.2x
|
2.4x
|
| Price / FCF |
32.2x
|
16.5x
|
| Revenue Growth YoY |
+16.2%
|
-1.2%
|
| Gross Margin |
49.0%
|
70.3%
|
| Operating Margin |
29.7%
|
24.7%
|
| Return on Equity |
49.2%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.1%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Netflix, Inc. operates a leading global streaming entertainment service with a dominant streaming segment accounting for nearly 100% of its revenue. The company benefits from a high-quality business model characterized by strong revenue growth of 16.2% and earnings growth of 82.8% in the most recent quarter, a robust 49.2% return on equity, and healthy margins with a 29.7% operating margin and 28…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
NFLX |
PFE |
| Zone Low |
$133.57 |
$26.74 |
| Zone High |
$151.38 |
$30.30 |
| In Buy Zone? |
Yes
|
Yes
|